Kaitlyn D’Onofrio

Lung Cancers Today

A recent study found that durvalumab&nbsp;extended&nbsp;survival rates in some patients with&nbsp;stage III, unresectable non&ndash;small-cell lung cancer (NSCLC).Researchers randomly assigned 709 NSCLC patients&nbsp;who did not have disease progression after concurrent chemoradiotherapy&nbsp;to receive&nbsp;durvalumab&nbsp;(n = 473)&nbsp;intravenously, at a dose of 10 mg per kilogram of body weight, or matching placebo&nbsp;(n = 236)&nbsp;every&nbsp;two&nbsp;weeks for up to 12 months.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Does the PACIFIC trial indicate the best time to begin durvalumab? Hear what the faculty have to say: <a href="https://twitter.com/hashtag/lcsm?src=hash&amp;ref_src=twsrc%5Etfw">#lcsm</a> <a href="https://twitter.com/hashtag/stateofscience?src=hash&amp;ref_src=twsrc%5Etfw">#stateofscience</a> <a href="https://twitter.com/MontefioreNYC?ref_src=twsrc%5Etfw">@MontefioreNYC</a> <a href="https://twitter.com/AtlanticHealth?ref_src=twsrc%5Etfw">@AtlanticHealth</a> <a href="https://twitter.com/DrHaigentz?ref_src=twsrc%5Etfw">@DrHaigentz</a> <a href="https://twitter.com/HosseinBorghaei?ref_src=twsrc%5Etfw">@HosseinBorghaei</a> <a href="https://twitter.com/FoxChaseCancer?ref_src=twsrc%5Etfw">@FoxChaseCancer</a> <a href="https://t.co/SI30XeMNPR">pic.twitter.com/SI30XeMNPR</a>
&mdash; OncLive SOSS (@OncLiveSOSS) <a href="https://twitter.com/OncLiveSOSS/status/1050193779662233600?ref_src=twsrc%5Etfw">October 11, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>After two years, the survival rate in the&nbsp;durvalumab&nbsp;group&nbsp;was 66.3% (95% confidence interval [CI], 61.7 to 70.4)&nbsp;and&nbsp;55.6% (95% CI, 48.9 to 61.8) in the placebo group (two-sided P&nbsp;=&nbsp;0.005). Median progression-free survival rates were 17.2 months for the&nbsp;durvalumab&nbsp;group and 5.6 months in the placebo group&nbsp;(stratified hazard ratio for disease progression or death, 0.51; 95% CI, 0.41 to 0.63).&nbsp;In the&nbsp;durvalumab&nbsp;cohort, median time to death or distant metastasis was 28.3 months, compared to 16.2 months in the placebo cohort&nbsp;(stratified hazard ratio, 0.53; 95% CI, 0.41 to 0.68).&nbsp;Grade 3 or 4 adverse events of any cause occurred in 30.5% of the&nbsp;durvalumab&nbsp;patients and 26.1% of the placebo patients&mdash;15.4% and 9.8% of patients, respectively, dropped out of the trial due to adverse events.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Non-small cell lung cancer patients see improved survival with durvalumab <a href="https://twitter.com/MDLinx?ref_src=twsrc%5Etfw">@MDLinx</a> <a href="https://t.co/6DRyCfJCZl">https://t.co/6DRyCfJCZl</a>
&mdash; Anthony M Magliocco MD (@MaglioccoTony) <a href="https://twitter.com/MaglioccoTony/status/1049162064726556672?ref_src=twsrc%5Etfw">October 8, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>After the intervention, placebo patients were more likely to receive subsequent anticancer therapy than those who had received&nbsp;durvalumab&nbsp;(54% vs 41%).&nbsp;Thirty percent (n = 71) of the placebo group and 26.9% (n = 128) went on to receive cytotoxic chemotherapy; 22.4% (n = 53) and 8% (n = 38) patients, respectively, received additional immunotherapy; 13.1% (n = 31) and 9.9% (n = 47) patients, respectively, received non&mdash;immunotherapy-based targeted therapy; and 23.6% (n = 56) of placebo patients and 17.2% (n = 82) of&nbsp;durvalumab&nbsp;patients received radiotherapy.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Durvalumab after Chemoradiation for Advanced Non&ndash;Small-Cell Lung Cancer: Superior survival <a href="https://t.co/k3HpOZdjFO">https://t.co/k3HpOZdjFO</a> <a href="https://t.co/xldncn3kSZ">pic.twitter.com/xldncn3kSZ</a>
&mdash; NEJM Journal Watch (@JWatch) <a href="https://twitter.com/JWatch/status/1050160329311817729?ref_src=twsrc%5Etfw">October 10, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>One of the study&rsquo;s limitations is researchers had incomplete data on previous treatment, so causality for some adverse effects or risk factors could not be determined.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
If it is questionable, multidisciplinary discussion. Come to a conclusion about resectability, then actions can follow from that. Outcomes for stage III remain unacceptably poor. Durvalumab improves outcomes for some patients, but like all IO it is hardly a panacea
&mdash; Joshua Bauml, MD (@Jbauml) <a href="https://twitter.com/Jbauml/status/1049406852755324930?ref_src=twsrc%5Etfw">October 8, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The study authors concluded that the study &ldquo;showed a survival advantage with&nbsp;durvalumab&nbsp;therapy after concurrent chemoradiation therapy in patients with stage III, unresectable NSCLC.&rdquo;&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/chemotherapy-linked-menopause/">Chemotherapy Linked to Early Menopause in Women&nbsp;With&nbsp;Lung Cancer</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/study-lung-cancer-expected-decline/">Study: Lung Cancer Incidence Expected to Decline in Next 5 Decades</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/lung-cancer-deaths-women/">Lung Cancer Deaths for Women Projected to Increase Worldwide</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/future-of-medicine-picks/nyu-researchers-using-google-ai-to-determine-lung-cancer-type/">NYU Researchers Using Google AI to Determine Lung Cancer Type</a>Source:&nbsp;<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1809697">NEJM</a>

Lung Cancers Today Editors

Alice T. Shaw, MD, PhD, to Receive AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research

ALK+ NSCLC

Cecilia Brown

Can Patients With NSCLC Experience Durable Disease Control After ICI Discontinuation?

Immunotherapy in NSCLC

KROCUS Study Evaluates Fulzerasib Plus Cetuximab for NSCLC With KRAS Alteration

ELCC 2025

Nicolas Girard, MD, PhD

Laura Litwin

Dr. Girard Discusses Results From PALOMA-2

Phase 3 DeLLphi-304 Trial: Tarlatamab Shows Significant OS Improvement in SCLC

Small Cell Lung Cancer

Martin Reck, MD, PhD

Dr. Reck Shares Insights From Novel Immunotherapies Session at ELCC 2025

Latest News

Durvalumab Reduces Mortality Rate in Stage III Lung Cancer Patients

Non-Small Cell Lung Cancer

A recent study found that durvalumab extended survival rates in some patients with stage III, unresectable non–small-cell lung cancer (NSCLC).
 ...